EA202091486A1 - Способы и композиции для поляризации макрофагов - Google Patents

Способы и композиции для поляризации макрофагов

Info

Publication number
EA202091486A1
EA202091486A1 EA202091486A EA202091486A EA202091486A1 EA 202091486 A1 EA202091486 A1 EA 202091486A1 EA 202091486 A EA202091486 A EA 202091486A EA 202091486 A EA202091486 A EA 202091486A EA 202091486 A1 EA202091486 A1 EA 202091486A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
polarization
macrophages
macrophages polarization
Prior art date
Application number
EA202091486A
Other languages
English (en)
Inventor
Срирам Сатьянарайанан
Дуглас Е. Уилльямс
Далия Бурзын
Адам Томас Боутин
Сушрут Камеркар
Original Assignee
Кодиак Байосайенсес, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кодиак Байосайенсес, Инк. filed Critical Кодиак Байосайенсес, Инк.
Publication of EA202091486A1 publication Critical patent/EA202091486A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Abstract

В настоящем документе раскрыты композиции и способы, включающие внеклеточные везикулы, содержащие нуклеиновую кислоту, нацеленную на гены, что приводит к поляризации опухолеассоциированных макрофагов. В определенных вариантах осуществления в настоящем документе раскрыты способы и композиции для увеличения поляризации макрофагов с целью лечения онкологического заболевания.
EA202091486A 2018-02-12 2019-02-12 Способы и композиции для поляризации макрофагов EA202091486A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862629563P 2018-02-12 2018-02-12
PCT/US2019/017731 WO2019157535A1 (en) 2018-02-12 2019-02-12 Methods and compositions for macrophage polarization

Publications (1)

Publication Number Publication Date
EA202091486A1 true EA202091486A1 (ru) 2021-02-08

Family

ID=65729420

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091486A EA202091486A1 (ru) 2018-02-12 2019-02-12 Способы и композиции для поляризации макрофагов

Country Status (17)

Country Link
US (2) US11512315B2 (ru)
EP (1) EP3752615A1 (ru)
JP (1) JP2021512608A (ru)
KR (1) KR20200120624A (ru)
CN (1) CN111918967A (ru)
AU (1) AU2019218991A1 (ru)
BR (1) BR112020016228A2 (ru)
CA (1) CA3088009A1 (ru)
CL (1) CL2020002053A1 (ru)
CO (1) CO2020009694A2 (ru)
EA (1) EA202091486A1 (ru)
IL (1) IL276409A (ru)
MX (1) MX2020008103A (ru)
PH (1) PH12020551195A1 (ru)
SG (1) SG11202006021SA (ru)
TW (1) TW202003846A (ru)
WO (1) WO2019157535A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091486A1 (ru) 2018-02-12 2021-02-08 Кодиак Байосайенсес, Инк. Способы и композиции для поляризации макрофагов
WO2020106772A1 (en) * 2018-11-19 2020-05-28 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
EP4013457A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle linked to molecules and uses thereof
CA3147366A1 (en) * 2019-08-14 2021-02-18 Adam T. BOUTIN Extracellular vesicles with stat3-antisense oligonucleotides
CA3147369A1 (en) * 2019-08-14 2021-02-18 Dalia BURZYN Extracellular vesicle-aso constructs targeting cebp/beta
CN114641570A (zh) * 2019-08-14 2022-06-17 科迪亚克生物科学公司 具有靶向kras的反义寡核苷酸的细胞外囊泡
CA3147680A1 (en) * 2019-08-14 2021-02-18 Dalia BURZYN Extracellular vesicle-aso constructs targeting stat6
AU2020355240A1 (en) * 2019-09-25 2022-04-21 Lonza Sales Ag Extracellular vesicle compositions
AU2020398177A1 (en) * 2019-12-05 2022-07-07 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis
WO2021237100A1 (en) * 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN111748523B (zh) * 2020-07-17 2022-11-22 南通大学 一种免疫调节小胞外囊泡的制备方法及其用途
WO2022076596A1 (en) * 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN113262305B (zh) * 2021-05-27 2022-03-25 浙江大学 Coro1a基因作为靶点在制备抗肿瘤药物中的应用
WO2023277656A1 (ko) 2021-07-02 2023-01-05 (주)스파크바이오파마 벤조피란 유도체 및 이의 용도
CN113521252B (zh) * 2021-07-29 2022-12-20 南开大学 Tnfsf15蛋白作为巨噬细胞免疫增强剂的用途及其活化方法
WO2023069628A2 (en) * 2021-10-21 2023-04-27 Nanothera Biosciences, Inc. Compositions and methods for silencing kras
CN114058621B (zh) * 2021-12-03 2023-06-16 温州医科大学 一种lncRNA基因修饰细胞分泌的外泌体及应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114561347A (zh) * 2022-02-25 2022-05-31 和携科技有限公司 一种脂肪间充质干细胞的培养基和培养方法
CN115137708B (zh) * 2022-06-24 2023-05-16 重庆医科大学 装载yap1核酸序列的肝纤维化靶向纳米颗粒及其制备方法和应用
WO2024015512A1 (en) * 2022-07-13 2024-01-18 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
CN115261410A (zh) * 2022-07-20 2022-11-01 中山大学 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用
WO2024044788A2 (en) * 2022-08-26 2024-02-29 Georgia State University Research Foundation, Inc. Treating chronic inflammation and cancer by macrophage polarization
CN115814108A (zh) * 2022-12-27 2023-03-21 华中科技大学 一种用于个性化肿瘤治疗的工程化巨噬细胞载药微颗粒制剂及其制备方法
KR102635831B1 (ko) * 2023-11-01 2024-02-13 강원대학교 산학협력단 Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098797A2 (en) * 2000-06-19 2001-12-27 Halliburton Energy Services, Inc. Apparatus and methods for applying time lapse vsp to monitor a reservoir
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2014082083A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
WO2015058148A1 (en) * 2013-10-17 2015-04-23 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2016062722A1 (en) * 2014-10-24 2016-04-28 Astrazeneca Ab Combination
JP2018520125A (ja) * 2015-06-10 2018-07-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患の処置のためのエキソソームの使用
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
TW201723176A (zh) * 2015-09-24 2017-07-01 Ｉｏｎｉｓ製藥公司 Ｋｒａｓ表現之調節劑
WO2017161010A1 (en) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Therapeutic membrane vesicles
EP3500244A4 (en) 2016-08-22 2020-05-13 Codiak BioSciences, Inc. METHOD FOR SUPPRESSING THE DELIVERY OF EXOSOMES TO LIVER AND SPLEEN
CA3072352A1 (en) 2017-08-25 2019-02-28 Codiak Biosciences, Inc. Preparation of therapeutic exosomes using membrane proteins
EA202091486A1 (ru) 2018-02-12 2021-02-08 Кодиак Байосайенсес, Инк. Способы и композиции для поляризации макрофагов
EP4013457A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle linked to molecules and uses thereof
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
WO2023165615A1 (en) * 2022-03-04 2023-09-07 I-Mab Biopharma Co., Ltd. Combination therapies comprising a kras inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
BR112020016228A2 (pt) 2020-12-08
EP3752615A1 (en) 2020-12-23
CL2020002053A1 (es) 2020-12-18
US20230365971A1 (en) 2023-11-16
AU2019218991A1 (en) 2020-07-09
TW202003846A (zh) 2020-01-16
JP2021512608A (ja) 2021-05-20
KR20200120624A (ko) 2020-10-21
SG11202006021SA (en) 2020-08-28
CO2020009694A2 (es) 2020-10-30
US20200407725A1 (en) 2020-12-31
US11512315B2 (en) 2022-11-29
IL276409A (en) 2020-09-30
WO2019157535A1 (en) 2019-08-15
CN111918967A (zh) 2020-11-10
PH12020551195A1 (en) 2021-08-16
MX2020008103A (es) 2020-09-25
CA3088009A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
EA202091486A1 (ru) Способы и композиции для поляризации макрофагов
CY1124487T1 (el) Στοχευμενοι παραγοντες υψηλης-συγγενειας σε συγκεκριμενο αντιγονο μεμβρανης για προστατη για ενδοακτινοθεραπεια καρκινου του προστατη
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12018502429A1 (en) Antibody molecules for cancer treatment
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
CY1124568T1 (el) Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
GB2557123A (en) Modified cells and methods of therapy
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
AU2016278853A8 (en) Petrolatum-based compositions comprising cationic biocides
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
EP3630733A4 (en) PROSTATE SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINE AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2023005996A (es) Antiandrogenos para el tratamiento de cancer de prostata no metastasico resistente a la castracion.
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
MX2019000600A (es) Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.